Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 12.42% and Operating profit at 5.21% over the last 5 years
2
Flat results in Sep 25
3
With ROE of 6.92%, it has a very expensive valuation with a 5.10 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 18,971 Million (Large Cap)
74.00
NA
0.43%
0.32
6.74%
3.25
Revenue and Profits:
Net Sales:
986 Million
(Quarterly Results - Sep 2025)
Net Profit:
172 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.85%
0%
-11.85%
6 Months
-40.26%
0%
-40.26%
1 Year
-16.45%
0%
-16.45%
2 Years
-5.84%
0%
-5.84%
3 Years
-24.01%
0%
-24.01%
4 Years
-25.25%
0%
-25.25%
5 Years
-60.5%
0%
-60.5%
Betta Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.42%
EBIT Growth (5y)
5.21%
EBIT to Interest (avg)
9.58
Debt to EBITDA (avg)
1.94
Net Debt to Equity (avg)
0.31
Sales to Capital Employed (avg)
0.36
Tax Ratio
5.06%
Dividend Payout Ratio
20.68%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.85%
ROE (avg)
7.69%
Valuation key factors
Factor
Value
P/E Ratio
74
Industry P/E
Price to Book Value
5.10
EV to EBIT
65.73
EV to EBITDA
32.37
EV to Capital Employed
4.10
EV to Sales
9.81
PEG Ratio
NA
Dividend Yield
0.29%
ROCE (Latest)
6.24%
ROE (Latest)
6.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
985.90
813.90
21.13%
Operating Profit (PBDIT) excl Other Income
198.60
206.40
-3.78%
Interest
18.60
17.20
8.14%
Exceptional Items
28.00
0.60
4,566.67%
Consolidate Net Profit
172.30
35.20
389.49%
Operating Profit Margin (Excl OI)
201.50%
87.00%
11.45%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 21.13% vs -11.30% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 389.49% vs -63.14% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,884.00
2,442.10
18.10%
Operating Profit (PBDIT) excl Other Income
848.00
583.10
45.43%
Interest
46.90
56.50
-16.99%
Exceptional Items
-53.80
-4.90
-997.96%
Consolidate Net Profit
387.00
333.60
16.01%
Operating Profit Margin (Excl OI)
165.10%
114.50%
5.06%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 18.10% vs 3.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 16.01% vs 167.31% in Dec 2023
About Betta Pharmaceuticals Co., Ltd. 
Betta Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






